The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic review

BMC Gastroenterol. 2021 Dec 15;21(1):469. doi: 10.1186/s12876-021-02003-0.

Abstract

Objective: Cognitive behavioral therapy (CBT) is now included in the treatment of patients with inflammatory bowel disease (IBD) in many settings. However, different clinical trials report different outcomes without consensus. This study aims to evaluate the impact of CBT on the mental state, quality of life and disease activity of patients with IBD.

Design: Systematic review.

Methods: This systematic review searched eligible studies from 1946 to December 8, 2019, in MEDLINE, EMBASE, CINAHL, Cochrane library, ClinicalTrials.gov, PsycINFO, Web of Science for eligible randomized controlled trials (RCT).

Results: Among the initial identified 1807 references, 11 studies met inclusion criteria. CBT was shown to improve patient's quality of life and reduce the level of depression and anxiety post-intervention but was not sustained. Evidence is not enough for the effect of CBT on disease activity, or C-reactive protein level.

Conclusions: CBT has shown short-term positive psychological effects on IBD patients, but there is insufficient evidence for sustained physical and psychological improvements of IBD patients. PROSPERO registration: CRD42019152330.

Keywords: Cognitive behavior therapy; Crohn's disease; Depression; Inflammatory bowel disease; Quality of life; Ulcerative colitis.

Publication types

  • Systematic Review

MeSH terms

  • COVID-19*
  • Chronic Disease
  • Cognitive Behavioral Therapy*
  • Humans
  • Inflammatory Bowel Diseases* / therapy
  • SARS-CoV-2